Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

20th EURETINA Congress, Amsterdam 2020

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues and Friends,

2020 will be remembered as a year like no other. The worldwide upheaval presented by SARS-CoV-2 is having a monumental impact on how we live our day-to-day lives, as we navigate through this pandemic.

The Board of EURETINA has carefully considered the impact of recent events on the viability of hosting the annual Congress, from both ethical and practical perspectives. Due to the scale of the meeting and the global spread of its audience, it has been decided in agreement with our colleagues in ESCRS, EuCornea and WSPOS, that in the interest of health and safety it will regrettably not be possible to host a live event in Amsterdam this October.

As the annual Congress is an incredibly important event for the Society, we are delighted to announce that we are instead developing a virtual congress experience for 2020. This virtual meeting is expected to take place from 2-4 October with a stream of live and pre-recorded adapted programme content, which will be available on demand after the event.

As usual, we are working hard to deliver the highest quality scientific content curated by world-renowned experts in the field of retina. Specific details will be announced through the website over the coming months. The virtual meeting will be a new endeavour for the Society and one which will allow us to extend the reach of EURETINA. We are excited at this prospect and truly hope that you will join us for the 20th Congress as we come together to exchange new ideas and learnings from our medical community.

Wishing you and your families and colleagues health and well-being during this time.

Yours sincerely,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA


Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA

© EURETINA All rights reserved
Loading please wait